News and Treatment Updates

Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for aplastic anemia (AA), especially in younger patients with matched sibling donors (MSD). However, in low-resource settings, delayed access to HSCT and pre-transplant complications can…

Aged individuals with somatic TP53 mutations manifest clonal hematopoiesis (CH) and are at high risk of developing myeloid neoplasms. However, the underlying mechanisms are not fully understood. Here we show that inflammatory stress confers a competitive advantage to p53 mutant…

Abstract NRAS and KRAS mutations, commonly identified alongside ancestral co-mutations, are generally regarded as pathogenic in adults presenting with monocytosis and/or cytopenia(s). However, their significance in isolation is not well defined. We studied a multi-institutional…

To the Editor, We present the first prospective, multicenter, randomized controlled trial (RCT) evaluating Basiliximab prophylaxis for acute graft-versus-host disease (GVHD) in thalassemia major (TM) patients undergoing Matched unrelated donor hematopoietic stem-cell…

NIH clinical trial shows promise for people with treatment-limited, life-threatening disorder. A clinical trial at the National Institutes of Health (NIH) has shown that an experimental treatment for patients with severe aplastic anemia resulted in a 94% survival rate without…

Summary Many veterans and doctors have long questioned whether Agent Orange (AO) exposure during the Vietnam War contributed to cases of myelodysplastic syndrome (MDS), a type of blood cancer. The contaminated chemical is linked to several cancers, but a link to MDS was unclear…

Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…

Chemotherapy-free approaches could offer comparable efficacy with less toxicity (ORLANDO, Dec. 7, 2025) — Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for…

Highlights Heme biosynthesis enzymes are variably suppressed in AML Heme levels are linked with altered leukemic transcriptional programs via BACH1 Heme biosynthesis is a selective dependency in AML, both in vitro and in vivo Heme starvation disrupts complex IV, inducing copper…

Abstract Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM)…